OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

Recordati Industria Chimica e Far.../  IT0003828271  /

Cboe Europe DXE
6/2/2023  5:35:30 PM Chg. +0.45 Volume Bid5:35:30 PM Ask5:35:30 PM Market Capitalization Dividend Y. P/E Ratio
42.94EUR +1.06% 116,207
Turnover: 2.27 mill.		 -Bid Size: - -Ask Size: - 8.8 bill.EUR 2.68% 28.20
GlobeNewswire 3/23/2021 RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S AN...
GlobeNewswire 2/22/2021 RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBI...
GlobeNewswire 1/29/2021 RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES
GlobeNewswire 11/30/2020 RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEA...
GlobeNewswire 10/29/2020 RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NE...
GlobeNewswire 10/1/2020 RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P....
GlobeNewswire 9/21/2020 RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION
GlobeNewswire 7/30/2020 RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET IN...
GlobeNewswire 6/17/2020 RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S D...
GlobeNewswire 5/7/2020 RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%
GlobeNewswire 4/29/2020 RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018)
GlobeNewswire 4/8/2020 Recordati Rare Diseases now holds Isturisa® European MA
GlobeNewswire 3/26/2020 RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN
GlobeNewswire 3/18/2020 RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY D...
GlobeNewswire 3/18/2020 BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). ...
GlobeNewswire 2/14/2020 RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBIT...
GlobeNewswire 1/15/2020 RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED
GlobeNewswire 11/15/2019 RECORDATI: CHMP ADOPTS POSITIVE OPINION FOR ISTURISA® (OSILODROSTAT)
GlobeNewswire 10/31/2019 RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING IN...
GlobeNewswire 10/23/2019 RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED
GlobeNewswire 7/30/2019 RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA(1) +7.4%, NET INCOME +6.1%
GlobeNewswire 7/12/2019 RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699)
GlobeNewswire 6/24/2019 RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS
GlobeNewswire 5/8/2019 RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2019. NEW THREE YEAR BUSINESS PLAN APPROVED
GlobeNewswire 4/15/2019 RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY